Download PDF
Thromb Haemost 1999; 82(02): 892-898
DOI: 10.1055/s-0037-1615928
Research Article
Schattauer GmbH

Long-Term Treatment of Venous Thromboembolic Disease

Martin H. Prins
1   Department of Clinical Epidemiology & Biostatistics, Amsterdam, THE NETHERLANDS
,
Barbara A. Hutten
1   Department of Clinical Epidemiology & Biostatistics, Amsterdam, THE NETHERLANDS
,
Maria M.W. Koopman
2   Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, THE NETHERLANDS
,
Harry R. Büller
2   Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, THE NETHERLANDS
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

After an initial 5- to 10-day course of treatment with either unfractionated or low molecular weight heparin, secondary prophylaxis is usually prescribed to patients with venous thromboembolic disease for a variable period of time. The primary aim of both initial and secondary treatment is to prevent recurrent thrombotic events, including deep vein thrombosis and fatal pulmonary embolism. This objective has to be achieved at a minimal risk of bleeding. There is general consensus that the initial treatment should be with low molecular weight or unfractionated heparin. For secondary prophylaxis, however, there are currently several options. Among these are continued unfractionated heparin or low molecular weight heparin and oral vitamin K-antagonists. In addition, compression stockings and caval vein filters are available.

In this chapter, we will first examine the available evidence for each of these options, then discuss the results of randomized trials that have studied the duration of secondary prophylaxis. Finally, we will attempt to synthesize this information using decision analytic techniques.

 

  • References

  • 1 Barrit DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; I: 1309-12.
    PubMedGoogle Scholar
  • 2 Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985; II: 515-18.
    PubMedGoogle Scholar
  • 3 Hull RD, Delmore T, Genton E, Hirsch J, Gent M, Sackett D, McLaughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94
    CrossrefPubMedGoogle Scholar
  • 4 Hull RD, Hirsch J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-81.
    CrossrefPubMedGoogle Scholar
  • 5 Hull RD, Delmore T, Carter C, Hirsch J, Genton E, Gent M, Turpie G, McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
    CrossrefPubMedGoogle Scholar
  • 6 Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-97.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications for coumarin. Thromb Haemost 1994; 71: 7-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simmoneau G. A clinical trial of vena caval vein filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409-415.
    CrossrefPubMedGoogle Scholar
  • 9 Brandjes DP, Büller HR, Heijboer H, Huisman MV, De Rijk M, Jagt H, Ten Cate JW. A randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349 (9054) 759-62.
    CrossrefPubMedGoogle Scholar
  • 10 Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336 (06) 393-8.
    CrossrefPubMedGoogle Scholar
  • 11 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332 (25) 1661-5.
    CrossrefPubMedGoogle Scholar
  • 12 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74 (02) 606-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340 (8824) 873-6.
    PubMedGoogle Scholar
  • 14 Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA. A comparison of 3 and 6 weeks’ anticoagulation in the treatment of venous thromboembolism. Clinical & Laboratory Haematology 1987; 9 (01) 17-21.
    CrossrefPubMedGoogle Scholar
  • 15 Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. A randomized study. Acta Med Scand 1985; 217 (05) 547-52.
    PubMedGoogle Scholar
  • 16 Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 179-84.
    PubMedGoogle Scholar
  • 17 O’Sullivan EF. Duration of anticoagulant therapy in venous thrombo-embolism. Med J Aust 1972; 2: 1104-7.
    PubMedGoogle Scholar
  • 18 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 19 Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996; 76 (01) 12-6
    PubMedGoogle Scholar
  • 20 Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
    CrossrefPubMedGoogle Scholar
  • 21 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. on behalf of the ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy) Study Group. Bleeding complications of oral anticoagulant treatment: An inception cohort, prospective, collaborative study (ISCOAT). Lancet 1996; 348: 423-28.
    CrossrefPubMedGoogle Scholar
  • 22 Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (Factor V Leiden). N Engl J Med 1997; 336: 399-403.
    CrossrefPubMedGoogle Scholar
  • 23 Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with factor V Leiden mutation in a United Kingdom population. Thromb Haemostas 1996; 77: 440-3.
    PubMedGoogle Scholar
  • 24 Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of bleeding during anticoagulant treatment for venous thromboembolism. Arch Int Med. In press.
    PubMedGoogle Scholar
  • 25 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Büller HR. The incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to malignancy and achieved INR. Submitted.
    PubMedGoogle Scholar
  • 26 Van den Besselaar AMHP, Breddin K, Lutze G, Parker-Williams J, Taborski U, Vogel G, Trichler W, Zerback R, Leinberger L. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coagul Fibrinol 1995; 6: 726-732.
    CrossrefPubMedGoogle Scholar
  • 27 Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 1998; 3: 67-73.
    CrossrefPubMedGoogle Scholar
  • 28 Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-7.
    CrossrefPubMedGoogle Scholar
  • 29 Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A. among others Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemostas 1999; 81: 26-31.
    PubMedGoogle Scholar
  • 30 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs M, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Eng J Med 1999; 340 (12) 91-7.
    PubMedGoogle Scholar